the present invention relates to a hunter syndrome therapeutic agent and more specifically to a hunter syndrome therapeutic agent which can reduce the number of hospital visits by hunter syndrome patients to twice a month or less, containing a first composition to be injected intravenously and a second composition to be injected subcutaneously, while exhibiting a medicinal effect equivalent to or greater than the conventional once-weekly iv injection, increases patient drug-taking adherence. compared to conventional therapeutic agents and treatment methods, and allows for greater patient well-being and convenience. The iv / sc co-injection method according to the present invention exhibits an equivalent or superior therapeutic effect compared to that of a conventional iv injection once a week, while allowing a patient to visit the hospital less often than once a week. week, as with conventional visits, replacing the conventional iv injection method once a week, requiring a patient to visit the hospital once a week, with sc injections whereby a predetermined number of iv injections can be done directly at home by a patient. Guardian of the patient. This is contrary to a conventional concept that the therapeutic effect achieved by an sc injection would not be greater than the therapeutic effect achieved by an iv injection. therefore, the present invention relates to a therapeutic agent and a method of treatment of which the effect of the treatment of hunter syndrome is dramatically improved over conventional technology.a presente invenção se refere a um agente terapêutico da síndrome de hunter e, mais especificamente, a um agente terapêutico da síndrome de hunter, que pode reduzir o número de visitas ao hospital por pacientes com síndrome de hunter para duas vezes por mês ou menos, contendo uma primeira composição a ser injetada por via intravenosa e uma segunda composição a ser injetada por via subcutânea, enquanto exibe um efeito medicinal equivalente ou maior do qu
